MIRA Pharmaceuticals' Oral Ketamine Analog Achieves Complete Normalization Of Neuropathic Pain In Animal Studies
MIRA Pharmaceuticals' Oral Ketamine Analog Achieves Complete Normalization Of Neuropathic Pain In Animal Studies
The study, conducted at Monday, MIRA Pharmaceuticals Inc. (NASDAQ:MIRA) stock is trading higher with a session volume of 9.7 million compared to the average volume of 4.98 million, as per data from Benzinga Pro.
星期一，MIRA製藥公司（納斯達克：MIRA）的股票交易量爲970萬，高於平均交易量498萬。這是根據Benzinga Pro的數據。
The company announced that a recent preclinical study in rats demonstrated that its oral ketamine analog, Ketamir-2, produced a significant reversal of neuropathic pain, induced by nerve ligation, culminating in a 100% normalization of pain thresholds at the highest dose.
該公司宣佈，最近在大鼠的預臨床研究中，其口服氯胺酮類似物Ketamir-2顯示出對神經性疼痛的顯著逆轉效果，該疼痛是由神經扎束引起的，在最高劑量下疼痛閾值恢復了100%。
This effect stands in stark contrast to traditional ketamine, which proved ineffective orally under the same experimental conditions.
這種效果與傳統的口服氯胺酮形成了鮮明的對比，在相同的實驗條件下，口服氯胺酮在治療上無效。
The study, conducted at Pharmaseed Ltd, utilized a nerve ligation model to replicate human neuropathic pain and specifically investigated mechanical allodynia.
該研究是在Pharmaseed Ltd進行的，利用神經扎束模型複製了人類神經性疼痛，並具體調查了機械性痛覺過敏。
The results showed:
結果顯示：
- Low oral doses of Ketamir-2 led to a significant reversal of pain for 14 and 22 days following the operation.
- Ketamir-2 achieved complete normalization of the pain threshold at a higher oral dose, representing a 100% reversal of the neuropathic pain signal.
- Ketamir-2的低口服劑量在手術後的14天和22天內顯著逆轉了疼痛。
- Ketamir-2在更高的口服劑量下實現了疼痛閾值的完全恢復，相當於對神經性疼痛信號進行100%的逆轉。
These outcomes underscore Ketamir-2's superior efficacy and highlight its potential as a transformative treatment for neuropathic pain, especially compared to oral ketamine, which did not deliver significant pain relief.
這些結果凸顯了Ketamir-2優越的療效，突出了其作爲神經性疼痛變革性治療的潛力，尤其與口服氯胺酮相比，後者沒有提供顯著的疼痛緩解。
MIRA Pharmaceuticals is conducting additional studies to evaluate Ketamir-2's efficacy in treating cancer-induced depression and neuropathic pain.
MIRA Pharmaceuticals正在進行額外的研究，以評估Ketamir-2治療癌症引起的抑鬱和神經病性疼痛的療效。
MIRA is optimistic that these efforts could demonstrate efficacy in humans as early as 2025.
MIRA非常樂觀地認爲，這些努力可能在2025年早期展示對人類的療效。
Itzchak Angel, Chief Scientific Advisor at MIRA Pharmaceuticals, added, "The ability to administer Ketamir-2 orally without the severe psychotropic side effects commonly associated with ketamine is a remarkable achievement. This positions Ketamir-2 as a pioneering treatment in the realm of neuropathic pain, offering hope to patients who have limited options available."
MIRA Pharmaceuticals的首席科學顧問Itzchak Angel補充道：「Ketamir-2能夠口服，而不會出現與氯胺酮常見的嚴重精神藥理副作用。這使得Ketamir-2成爲神經病性疼痛領域的開創性治療方法，爲那些治療選擇有限的患者帶來了希望。」
MIRA Pharmaceuticals continues to advance its research, focusing on scaling production and preparing for the next stages of clinical trials.
MIRA Pharmaceuticals繼續推進其研究工作，專注於擴大生產規模，爲下一階段的臨床試驗做準備。
In July, the company announced new insights from additional recently received preclinical study data regarding the mechanism of action and toxicology data for Ketamir-2.
今年7月，該公司宣佈了有關Ketamir-2的機制和毒理學數據的新見解，這些數據來自最近收到的額外臨床前研究數據。
Price Action: MIRA stock is up 39.4% at $2.579 during the premarket session at last check Monday.
股票表現：MIRA股價在週一盤前交易中上漲39.4%，至2.579美元。
Photo via Shutterstock
圖片來自shutterstock。
- Novo Nordisk Does Not Operate As Drug Cartel, CEO Defends US Pricing Of Ozempic Against Criticism Over High Drug Prices.
- Novo Nordisk不是以毒品販子的方式運作，CEO爲Ozempic的美國定價辯護，反對高藥價的批評。
譯文內容由第三人軟體翻譯。
